#China #Shenzhen #Global Expansion #Kexing Biopharm #IQVIA

Kexing Biopharm and IQVIA Partner for Global Expansion

Kexing Biopharm (688136.SH), a leading biopharmaceutical company based in Shenzhen, China, has recently announced a pivotal strategic alliance with IQVIA (NYSE: IQV), a global frontrunner in clinical research services, commercial analytics, and healthcare intelligence. This collaboration aims to accelerate Kexing’s global clinical development, regulatory approval processes, and the commercialization of its innovative drugs and biosimilars, particularly in key European and other regulated international markets.

In recent years, Kexing Biopharm has made significant strides toward internationalization by establishing a unique global platform that integrates advanced R&D capabilities with agile commercial execution. The company has successfully facilitated the international market entry of several high-quality pharmaceutical products. Its licensed nab-paclitaxel has achieved rapid approval and launch across multiple key jurisdictions, demonstrating Kexing’s capability in navigating complex regulatory landscapes.

Moreover, Kexing is actively expanding its R&D portfolio, with a focus on therapeutic areas including antiviral treatments, oncology, immunosuppressants, and metabolic diseases. The strategic partnership with IQVIA leverages the latter's deep expertise in global clinical trial design, regulatory strategy, and data-driven analytics to enhance the efficiency of clinical trials and expedite international market access. Through this collaboration, both companies aim to significantly strengthen Kexing’s global development capacity and hasten its transition to international biopharmaceutical innovation.

During the signing ceremony, Brian Mi, President of IQVIA Asia Pacific, commended Kexing's rapid progress in international marketing and product innovation. He emphasized that this collaboration will create new opportunities for both parties. Kexing Biopharm's CEO, Yanqing Zhao, also highlighted that IQVIA's extensive global resources in clinical data, patient insights, and regulatory expertise will play a crucial role in streamlining development strategies, improving success rates, and accelerating timelines for global registration.

Kexing Biopharm positions itself as an innovative biopharmaceutical entity dedicated primarily to the R&D, production, and commercialization of recombinant protein drugs and microecological preparations. The company primarily focuses on antiviral therapies and the treatment of various diseases, including tumors, autoimmune, metabolic, and degenerative conditions. By developing cutting-edge biotechnology platforms for novel proteins, antibodies, nucleic acids, and other therapeutic drugs, Kexing aims to realize its vision of transforming healthcare through biotechnology.

Following a model driven by innovation and internationalization, Kexing also explores the extensive application of biotechnology within the health sector. This strategic alliance underscores Kexing Biopharm's long-term commitment to international expansion through scientific rigor and efficient execution. Looking ahead, Kexing plans to deepen its global collaborations to bring more high-quality Chinese pharmaceutical innovations to patients worldwide, furthering its mission to improve global health outcomes.

In conclusion, the partnership between Kexing Biopharm and IQVIA represents a significant move in the biopharmaceutical landscape. By combining their respective strengths, both companies are well-positioned to make a substantial impact in the global market, ultimately benefiting patients needing innovative therapies across the globe.